Cargando…

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers

Immunotherapy with tumor-infiltrating lymphocytes (TIL) or oncolytic adenoviruses, have shown promising results in cancer treatment, when used as separate therapies. When used in combination, the antitumor effect is synergistically potentiated due oncolytic adenovirus infection and its immune stimul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santos, Joao, Heiniö, Camilla, Quixabeira, Dafne, Zafar, Sadia, Clubb, James, Pakola, Santeri, Cervera-Carrascon, Victor, Havunen, Riikka, Kanerva, Anna, Hemminki, Akseli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143525/ https://www.ncbi.nlm.nih.gov/pubmed/33922052 http://dx.doi.org/10.3390/cells10050978

Ejemplares similares

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022)

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
por: Kudling, Tatiana V., et al.
Publicado: (2022)

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
por: Quixabeira, Dafne C. A., et al.
Publicado: (2022)

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
por: Quixabeira, Dafne C. A., et al.
Publicado: (2021)

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
por: Heiniö, Camilla, et al.
Publicado: (2020)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
por: Pakola, Santeri, et al.
Publicado: (2023)

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer
por: Clubb, James H. A., et al.
Publicado: (2022)

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
por: Cervera-Carrascon, Victor, et al.
Publicado: (2021)

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine
por: Quixabeira, D. C. A., et al.
Publicado: (2023)

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
por: Kudling, Tatiana V., et al.
Publicado: (2023)

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
por: Zafar, Sadia, et al.
Publicado: (2020)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
por: Clubb, James H. A., et al.
Publicado: (2023)

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
por: Havunen, Riikka, et al.
Publicado: (2021)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
por: Havunen, Riikka, et al.
Publicado: (2016)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses
por: Taipale, Kristian, et al.
Publicado: (2015)

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
por: Taipale, Kristian, et al.
Publicado: (2018)

Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses
por: Kanerva, Anna, et al.
Publicado: (2008)

Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus
por: Ahtiainen, Laura, et al.
Publicado: (2010)

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment
por: Hirvinen, Mari, et al.
Publicado: (2013)

SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and (131)I
por: Rajecki, Maria, et al.
Publicado: (2012)

Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance
por: Tähtinen, Siri, et al.
Publicado: (2015)

Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus
por: Callegari, Elisa, et al.
Publicado: (2013)

Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy
por: Farzad, Lisa, et al.
Publicado: (2014)

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
por: Havunen, Riikka, et al.
Publicado: (2015)

Oncolytic Immunotherapy: Where Are We Clinically?
por: Hemminki, Akseli
Publicado: (2014)

Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma
por: Franco-Luzón, Lidia, et al.
Publicado: (2020)

MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver
por: Ylösmäki, Erkko, et al.
Publicado: (2013)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2018)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Portrait of a Leader in Immunotherapeutics: Oncolytic viruses for treatment of cancer
por: Hemminki, Akseli
Publicado: (2012)

Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism
por: Koski, Anniina, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sgvv18ci3uub6unnhv5ht692iq